Clearside Biomedical, Inc., a privately held ophthalmic company
developing and commercializing targeted therapeutics for the treatment
of sight-threatening diseases, today announced Rafael V. Andino has been
named to the position of Vice President, Product Development.
Andino has 25 years of experience in the pharmaceutical and medical
device industry in both public and private companies serving in product
development, research and development and general management roles. He
has led multidisciplinary and multinational teams to launch successful
products in many fields of medicine including ophthalmology, urology,
endourology, gynecology, wound care, cardiovascular and general surgery.
"Rafael's product development and leadership experience and his proven
ability to bring new products to market will be an invaluable asset to
us, and he will play an integral role in the leadership team we are
building at Clearside Biomedical," said Daniel White, president and CEO.
Andino has most recently been employed as Directo of R&D by Bard
Medical, a division of C.R. Bard, Inc., a top 20 global medical device
manufacturer with sales in excess of $2.5 billion (NYSE: BCR). Prior to
Bard, he founded and led Biofisica, Inc. which developed breakthrough
technology to expedite wound healing and regeneration of connective
tissue in humans. In 2007, Biofisica launched the first wound care
product of its kind, POSIFECT®, in the United Kingdom. Prior to founding
Biofisica, Andino was a R&D director and senior project manager for CIBA
VISION® (a Novartis company), a leading global contact lens and lens
care company. He has also worked for the global technology companies
E.I. Dupont, General Electric and IBM.
Andino obtained a Bachelor's degree in Mechanical Engineering from the
Georgia Institute of Technology, a Master of Science in Biomedical
Engineering from the University of Alabama at Birmingham and an MBA from
Mercer University in Atlanta, GA.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA is a
clinical-stage ophthalmic pharmaceutical company that develops and
commercializes targeted therapeutics to treat sight-threatening
diseases. Clearside treats the pathological changes to the blood retinal
barrier that lead to retinal blindness by delivering therapeutics
through the suprachoroidal space to the retina and choroid using a
proprietary microinjection dosage form. Clearside Biomedical was founded
by an executive team with extensive development and revenue growth
expertise. This team strives for better delivery and performance of its
therapeutic agents to improve the standard of care for patients with
retinal and choroidal disease. Visit http://www.clearsidebio.com/
for more information.
[ Back To NFVZone's Homepage ]